Recent approvals of CAR-T and gene therapy products have offered hope for a new era of Big Pharma innovation. But despite increasing investment and recent action from the FDA, the number of new drugs hitting pharmacy shelves has remained relatively constant over the last 20 years. Even when drugs do make it to the market, it is becoming increasingly difficult to gain reimbursement, and launch trajectories are slowing.
This panel will ask in the new world of pricing pressure and selected innovation, where are the pockets of excellence and where does pharma need to take a more radical approach to restructuring in order to fix broken paradigms. And with the increasing convergence of medtech and pharma, is it time to hand over to new entrants?
Ability Level: All
Session ID: 21117